PHARMA MAR, S.A. «12345...» Page 4 out of 11 from 01/07/1988 to 24/05/2018 The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish 26/07/2017 18:46 PHARMA MAR, S.A. Announcements of public presentations and meetings The Company announces that it plans to hold a teleconference with analysts and investors to comment on the financial results for the first half of 2017. Register number: 255060 26/07/2017 18:39 PHARMA MAR, S.A. Information on P&L The Company sends press release regarding first half 2017 results Register number: 255058 26/07/2017 18:32 PHARMA MAR, S.A. Interim financial information La sociedad remite información sobre los resultados del primer semestre de 2017 Register number: 255057 26/07/2017 08:27 PHARMA MAR, S.A. Credit ratings Axesor ratifies the rating of Pharma Mar, S.A. and its outlook as stable. Register number: 255012 10/07/2017 12:02 PHARMA MAR, S.A. Liquidity contracts and specialists The Company announces that has entered into a liquidity agreement with Mediación Bursátil, Sociedad de Valores, S.A. Register number: 254397 Related with 266338 of 01/06/2018 (11:07) 10/07/2017 11:14 PHARMA MAR, S.A. Liquidity contracts and specialists The Company announces the termination of the liquidity agreement entered into on May, 24, 2017 with MEDIACIÓN BURSÁTIL, SOCIEDAD DE VALORES, S.A. Register number: 254394 29/06/2017 14:04 PHARMA MAR, S.A. Announcements and resolutions of general shareholders meetings. - Employees share and stock ownership schemes It is reported that all proposed resolutions submitted by the Board to the General Shareholders’ Meeting have been approved. Register number: 254038 Related with 252524 of 26/05/2017 (14:39) 29/06/2017 10:26 PHARMA MAR, S.A. Strategic plans, profit forecasts and presentations. - Announcements and resolutions of general shareholders meetings Attached is a copy of the presentation to shareholders to be made at the General Shareholders’ Meeting of Pharma Mar by the Chairman and by the Chief Financial Officer of the Company. Register number: 254005 01/06/2017 17:45 PHARMA MAR, S.A. Increases and decreases of share capital. - Trading: admissions, changes and removals The Company announces the admission to trading of the shares relating to the share capital increase Register number: 252694 29/05/2017 19:23 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks. - Announcements of public presentations and meetings Sylentis, S.A.U. has initiated the first Phase III study, HELIX, with its investigational drug SYL1001 for the treatment of dry eye syndrome Register number: 252585 Page 4 out of 11 «12345...»